Raynaud's Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Update of EULAR recommendations for the treatment of systemic sclerosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- Annals of the rheumatic diseases1
Leading researchers8
- Allanore Y1
- Avouac J1
- Becker M1
- Clements P1
- Cutolo M1
- Czirjak L1
- Damjanov N1
- Del Galdo F1
Affiliations (unnormalised)6
- Basel University1
- Central Manchester NHS Foundation Trust1
- Cochin Hospital1
- Department of Rheumatology and Clinical Immunology1
- Ghent University Hospital1
- Hamburg Centre for Pediatric and Adolescence Rheumatology1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.